Starpharma Holdings Ltd (SPL) - Net Assets
Based on the latest financial reports, Starpharma Holdings Ltd (SPL) has net assets worth AU$13.78 Million AUD (≈ $9.75 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$19.02 Million ≈ $13.46 Million USD) and total liabilities (AU$5.24 Million ≈ $3.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Starpharma Holdings Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$13.78 Million |
| % of Total Assets | 72.44% |
| Annual Growth Rate | -2.8% |
| 5-Year Change | -71.53% |
| 10-Year Change | -77.41% |
| Growth Volatility | 44.58 |
Starpharma Holdings Ltd - Net Assets Trend (2000–2026)
This chart illustrates how Starpharma Holdings Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Starpharma Holdings Ltd market capitalisation.
Annual Net Assets for Starpharma Holdings Ltd (2000–2026)
The table below shows the annual net assets of Starpharma Holdings Ltd from 2000 to 2026. Also explore net asset momentum of Starpharma Holdings Ltd to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | AU$13.78 Million ≈ $9.75 Million |
-27.49% |
| 2025-06-30 | AU$19.00 Million ≈ $13.44 Million |
-32.43% |
| 2024-06-30 | AU$28.12 Million ≈ $19.89 Million |
-19.24% |
| 2023-06-30 | AU$34.81 Million ≈ $24.63 Million |
-28.06% |
| 2022-06-30 | AU$48.39 Million ≈ $34.24 Million |
-22.32% |
| 2021-06-30 | AU$62.30 Million ≈ $44.08 Million |
+98.88% |
| 2020-06-30 | AU$31.33 Million ≈ $22.17 Million |
-26.11% |
| 2019-06-30 | AU$42.40 Million ≈ $30.00 Million |
-20.43% |
| 2018-06-30 | AU$53.28 Million ≈ $37.70 Million |
-12.64% |
| 2017-06-30 | AU$60.98 Million ≈ $43.15 Million |
+23.39% |
| 2016-06-30 | AU$49.42 Million ≈ $34.97 Million |
+31.59% |
| 2015-06-30 | AU$37.56 Million ≈ $26.57 Million |
+13.98% |
| 2014-06-30 | AU$32.95 Million ≈ $23.31 Million |
-28.32% |
| 2013-06-30 | AU$45.97 Million ≈ $32.53 Million |
-5.51% |
| 2012-06-30 | AU$48.65 Million ≈ $34.42 Million |
+75.68% |
| 2011-06-30 | AU$27.69 Million ≈ $19.59 Million |
-20.52% |
| 2010-06-30 | AU$34.84 Million ≈ $24.65 Million |
+36.65% |
| 2009-06-30 | AU$25.50 Million ≈ $18.04 Million |
+25.10% |
| 2008-06-30 | AU$20.38 Million ≈ $14.42 Million |
-20.76% |
| 2007-06-30 | AU$25.72 Million ≈ $18.20 Million |
+20.68% |
| 2006-06-30 | AU$21.32 Million ≈ $15.08 Million |
+113.89% |
| 2005-06-30 | AU$9.97 Million ≈ $7.05 Million |
-43.35% |
| 2004-06-30 | AU$17.59 Million ≈ $12.45 Million |
+90.33% |
| 2003-06-30 | AU$9.24 Million ≈ $6.54 Million |
-46.47% |
| 2002-06-30 | AU$17.27 Million ≈ $12.22 Million |
-30.70% |
| 2001-06-30 | AU$24.92 Million ≈ $17.63 Million |
-13.65% |
| 2000-06-30 | AU$28.85 Million ≈ $20.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Starpharma Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25560602100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$240.75 Million | 1747.60% |
| Other Comprehensive Income | AU$32.84 Million | 238.41% |
| Total Equity | AU$13.78 Million | 100.00% |
Starpharma Holdings Ltd Competitors by Market Cap
The table below lists competitors of Starpharma Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boryszew SA
WAR:BRS
|
$273.52 Million |
|
Xperi Corp
NYSE:XPER
|
$273.61 Million |
|
Aurion Resources Ltd
V:AU
|
$273.63 Million |
|
Leonteq AG
SW:LEON
|
$273.70 Million |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
$273.20 Million |
|
COG Financial Services Ltd
AU:COG
|
$273.14 Million |
|
TSC Auto ID Technology Co Ltd
TWO:3611
|
$273.03 Million |
|
i3 Verticals Inc
NASDAQ:IIIV
|
$273.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Starpharma Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 18,998,000 to 13,776,000, a change of -5,222,000 (-27.5%).
- Net loss of 7,465,000 reduced equity.
- Other comprehensive income increased equity by 2,243,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.46 Million | -54.19% |
| Other Comprehensive Income | AU$2.24 Million | +16.28% |
| Total Change | AU$- | -27.49% |
Book Value vs Market Value Analysis
This analysis compares Starpharma Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.50x to 25.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-06-30 | AU$0.32 | AU$0.81 | x |
| 2001-06-30 | AU$0.30 | AU$0.81 | x |
| 2002-06-30 | AU$0.19 | AU$0.81 | x |
| 2003-06-30 | AU$0.10 | AU$0.81 | x |
| 2004-06-30 | AU$0.17 | AU$0.81 | x |
| 2005-06-30 | AU$0.09 | AU$0.81 | x |
| 2006-06-30 | AU$0.16 | AU$0.81 | x |
| 2007-06-30 | AU$0.16 | AU$0.81 | x |
| 2008-06-30 | AU$0.11 | AU$0.81 | x |
| 2009-06-30 | AU$0.14 | AU$0.81 | x |
| 2010-06-30 | AU$0.15 | AU$0.81 | x |
| 2011-06-30 | AU$0.11 | AU$0.81 | x |
| 2012-06-30 | AU$0.18 | AU$0.81 | x |
| 2013-06-30 | AU$0.16 | AU$0.81 | x |
| 2014-06-30 | AU$0.12 | AU$0.81 | x |
| 2015-06-30 | AU$0.12 | AU$0.81 | x |
| 2016-06-30 | AU$0.14 | AU$0.81 | x |
| 2017-06-30 | AU$0.17 | AU$0.81 | x |
| 2018-06-30 | AU$0.14 | AU$0.81 | x |
| 2019-06-30 | AU$0.11 | AU$0.81 | x |
| 2020-06-30 | AU$0.08 | AU$0.81 | x |
| 2021-06-30 | AU$0.16 | AU$0.81 | x |
| 2022-06-30 | AU$0.12 | AU$0.81 | x |
| 2023-06-30 | AU$0.09 | AU$0.81 | x |
| 2024-06-30 | AU$0.07 | AU$0.81 | x |
| 2025-06-30 | AU$0.05 | AU$0.81 | x |
| 2026-06-30 | AU$0.03 | AU$0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Starpharma Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -61.95%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 1.38x
- Recent ROE (-54.19%) is below the historical average (-31.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -6.14% | -110.06% | 0.06x | 1.01x | AU$-4.66 Million |
| 2001 | -15.68% | -198.88% | 0.08x | 1.04x | AU$-6.40 Million |
| 2002 | 0.31% | 13.82% | 0.02x | 1.11x | AU$-1.65 Million |
| 2003 | -1.89% | -11.79% | 0.14x | 1.16x | AU$-1.10 Million |
| 2004 | -31.25% | -395.36% | 0.08x | 1.05x | AU$-7.26 Million |
| 2005 | -76.12% | -370.18% | 0.16x | 1.25x | AU$-8.58 Million |
| 2006 | -35.29% | -1504557.80% | 0.00x | 1.17x | AU$-9.65 Million |
| 2007 | -28.16% | -838.68% | 0.03x | 1.18x | AU$-9.82 Million |
| 2008 | -36.75% | -530.52% | 0.06x | 1.21x | AU$-9.53 Million |
| 2009 | -16.18% | -204.41% | 0.07x | 1.13x | AU$-6.68 Million |
| 2010 | -18.30% | -454.27% | 0.04x | 1.08x | AU$-9.86 Million |
| 2011 | -32.25% | -780.59% | 0.04x | 1.08x | AU$-11.70 Million |
| 2012 | -28.07% | -1476.54% | 0.02x | 1.12x | AU$-18.52 Million |
| 2013 | -11.38% | -26145.00% | 0.00x | 1.06x | AU$-9.83 Million |
| 2014 | -44.41% | -1168.00% | 0.03x | 1.12x | AU$-17.93 Million |
| 2015 | -50.46% | -1116.68% | 0.04x | 1.18x | AU$-22.71 Million |
| 2016 | -43.08% | -465.50% | 0.08x | 1.19x | AU$-26.23 Million |
| 2017 | -24.95% | -417.25% | 0.05x | 1.09x | AU$-21.32 Million |
| 2018 | -19.30% | -207.48% | 0.08x | 1.10x | AU$-15.61 Million |
| 2019 | -33.62% | -524.04% | 0.06x | 1.15x | AU$-18.49 Million |
| 2020 | -46.86% | -243.30% | 0.15x | 1.25x | AU$-17.81 Million |
| 2021 | -31.67% | -1097.44% | 0.02x | 1.18x | AU$-25.96 Million |
| 2022 | -33.38% | -345.02% | 0.07x | 1.37x | AU$-20.99 Million |
| 2023 | -44.92% | -532.09% | 0.06x | 1.50x | AU$-19.12 Million |
| 2024 | -29.04% | -98.50% | 0.23x | 1.31x | AU$-10.98 Million |
| 2025 | -52.58% | -203.38% | 0.19x | 1.34x | AU$-11.89 Million |
| 2026 | -54.19% | -61.95% | 0.63x | 1.38x | AU$-8.84 Million |
Industry Comparison
This section compares Starpharma Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $15,249,806
- Average return on equity (ROE) among peers: -47.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Starpharma Holdings Ltd (SPL) | AU$13.78 Million | -6.14% | 0.38x | $273.41 Million |
| Adalta Ltd (1AD) | $7.49 Million | -79.00% | 0.24x | $6.31 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $14.35 Million | 39.55% | 0.08x | $14.31 Million |
| ACRUX Ltd (ACR) | $8.70 Million | -8.79% | 0.64x | $2.61 Million |
| Actinogen Medical Ltd (ACW) | $24.00K | 0.00% | 1.21x | $130.32 Million |
| Argenica Therapeutics Ltd (AGN) | $7.67 Million | -62.81% | 0.24x | $13.18 Million |
| Arovella Therapeutics Ltd (ALA) | $8.84 Million | -33.96% | 0.88x | $48.75 Million |
| Anatara Lifesciences Ltd (ANR) | $924.54K | -218.83% | 0.54x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $30.47 Million | -50.24% | 0.10x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $11.42 Million | -39.44% | 0.30x | $45.40 Million |
| Avecho Biotechnology Ltd (AVE) | $62.61 Million | -17.66% | 0.02x | $60.14 Million |
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRA… Read more